323 related articles for article (PubMed ID: 17327886)
1. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.
Wee S; Wang Z; Woolverton WL; Pulvirenti L; Koob GF
Neuropsychopharmacology; 2007 Oct; 32(10):2238-47. PubMed ID: 17327886
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.
Der-Ghazarian T; Charntikov S; Varela FA; Crawford CA; McDougall SA
J Neural Transm (Vienna); 2010 May; 117(5):573-83. PubMed ID: 20372943
[TBL] [Abstract][Full Text] [Related]
3. The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.
Orio L; Wee S; Newman AH; Pulvirenti L; Koob GF
Addict Biol; 2010 Jul; 15(3):312-23. PubMed ID: 20456290
[TBL] [Abstract][Full Text] [Related]
4. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole.
Bäckström P; Etelälahti TJ; Hyytiä P
Addict Biol; 2011 Jan; 16(1):55-63. PubMed ID: 21158016
[TBL] [Abstract][Full Text] [Related]
6. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Bergman J
Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats.
Nirogi R; Kandikere V; Jayarajan P; Bhyrapuneni G; Saralaya R; Muddana N; Abraham R
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):72-9. PubMed ID: 23421566
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice.
Sørensen G; Sager TN; Petersen JH; Brennum LT; Thøgersen P; Hee Bengtsen C; Thomsen M; Wörtwein G; Fink-Jensen A; Woldbye DP
Psychopharmacology (Berl); 2008 Jul; 199(1):37-46. PubMed ID: 18481046
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Oshibuchi H; Inada K; Sugawara H; Ishigooka J
Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Han M; Huang XF; Deng C
Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
[TBL] [Abstract][Full Text] [Related]
13. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
Tanahashi S; Yamamura S; Nakagawa M; Motomura E; Okada M
Neuropharmacology; 2012 Feb; 62(2):765-74. PubMed ID: 21925189
[TBL] [Abstract][Full Text] [Related]
15. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats.
Thomsen M; Fink-Jensen A; Woldbye DP; Wörtwein G; Sager TN; Holm R; Pepe LM; Caine SB
Psychopharmacology (Berl); 2008 Nov; 201(1):43-53. PubMed ID: 18612628
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans.
Lile JA; Stoops WW; Vansickel AR; Glaser PE; Hays LR; Rush CR
Neuropsychopharmacology; 2005 Nov; 30(11):2103-14. PubMed ID: 15988473
[TBL] [Abstract][Full Text] [Related]
19. Effects of extended access to high versus low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats.
Mantsch JR; Yuferov V; Mathieu-Kia AM; Ho A; Kreek MJ
Psychopharmacology (Berl); 2004 Aug; 175(1):26-36. PubMed ID: 15042275
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats.
Shuto T; Seeman P; Kuroiwa M; Nishi A
Eur J Neurosci; 2008 May; 27(10):2551-7. PubMed ID: 18489579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
